As it stands currently, PCa screenings that require longitudinal monitoring of PSA, such as PSAV and PSA doubling time are only of diagnostic benefit if with each repeated measurement, the clinical laboratory, PSA assay, and molecular form concentrations of the PSA and PSA-ACT calibrant remain exactly the same. This evidence concerns the gene KLK3 and posterior cortical atrophy.